Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases

Abstract

Patients undergoing cytotoxic or immunosuppressive therapy for cancer have an established predilection for hepatitis B virus reactivation; however, the risk associated with newer molecularly targeted agents has not been well investigated. Imatinib, a small molecule tyrosine kinase inhibitor, induces rapid and sustained clinical benefit by inhibiting a number of signaling pathways, including BCR-ABL and c-KIT. We report the case of a patient who developed hepatitis B virus reactivation while receiving imatinib therapy for gastrointestinal stromal tumor. Furthermore, a structured literature search of the medical databases consisting of MEDLINE and PubMed was performed using the terms “hepatitis B”, “reactivation”, and “imatinib”. The search identified nine case reports only. The data on patients’ characteristics, epidemiology, clinical features, comorbid conditions, diagnosis, and management are summarized. Imatinib-associated hepatitis B virus reactivation was reported in seven patients with chronic myeloid leukemia, one with desmoid tumor, and one with gastrointestinal stromal tumor. This review serves to outline our current understanding of the epidemiology, risk factors, and pathophysiology of chronic hepatitis B virus reactivation secondary to imatinib therapy as well as the current approaches to diagnosis and management of this condition. We aim to increase awareness about this possible association and advocate for hepatitis B virus screening prior to imatinib therapy, especially in patients who are at increased risk for chronic hepatitis B virus infection.

Keywords

Hepatitis B virus reactivation imatinib therapy gastrointestinal stromal tumor chronic myeloid leukemia

Get full access to this article

View all access options for this article.

References

Waller

. Imatinib mesylate. Recent Results Cancer Res 2014; 201: 1–25.

Inayat

Saif

. New drug and possible new toxicity – squamous cell carcinoma following imatinib in patients with gastrointestinal stromal tumors. Anticancer Res 2016; 36: 6201–6204.

Al Sobhi

Zahrani

Zevallos

et al.

Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007; 12: 49–53.

Ohyashiki

Kuriyama

Nakajima

et al.

Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002; 16: 2160–2161.

Saif

Smith

Maloney

et al.

Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Ann Gastroenterol 2016; 29: 551–556.

Hepatitis B: World Health Organization Fact Sheet 204. World Health Organization, www.who.int/mediacentre/factsheets/fs204/en/ (accessed 22 April 2018).

Pattullo

. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression – prevention is better than cure. World J Hepatol 2015; 7: 954–967.

Ikeda

Shiga

Takahashi

et al.

Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006; 47: 155–157.

Thia

Tan

Chuah

et al.

Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J 2008; 49: e86–e89.

10.

Kang

Lee

Moon

et al.

Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009; 90: 383–337.

11.

Kim

Chun

Jin

et al.

Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc 2010; 42: 843–835.

12.

Wang

Cui

et al.

Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J 2012; 125: 2636–2637.

13.

Lai

Yan

Chang

et al.

Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013; 19: 1318–1321.

14.

Lakhani

Davidson

Priebat

et al.

Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int 2008; 2: 498–499.

15.

Walker

Simko

. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res 2014; 34: 3629–3634.

16.

Wang

Cui

You

et al.

Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review. Zhonghua Xue Ye Xue Za Zhi 2012; 33: 743–746.

17.

Joensuu

Eriksson

Sundby Hall

et al.

Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol 2016; 34: 244–250.

18.

Rutkowski

Gronchi

Hohenberger

et al.

Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 2013; 20: 2937–2943.

19.

Demetri

von Mehren

Blanke

et al.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480.

20.

Dietz

Souan

Knutson

et al.

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1099.

21.

Cwynarski

Laylor

Macchiarulo

et al.

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.

22.

Daniels

JMA

Vonk-Noordegraaf

Janssen

JJWM

et al.

Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia. Eur Respir J 2009; 33: 670–672.

23.

Speletas

Vyzantiadis

T-A

Kalala

et al.

Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment. Med Mycol 2008; 46: 259–263.

24.

Maini

Boni

Ogg

et al.

Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology 1999; 117: 1386–1396.

25.

Raimondo G and Pollicino T. Occult HBV infection. Cham: Humana Press, pp. 277–301, http://link.springer.com/10.1007/978-3-319-22330-8_13 (2016, accessed April 2018).

26.

Voican

Mir

Loulergue

et al.

Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 2016; 27: 2172–2184.

27.

Tonyali

Coskun

Yildiz

et al.

Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol 2010; 27: 768–773.

28.

National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections, www.nccn.org/professionals/physician_gls/pdf/infections.pdf (2017, accessed 24 June 2018).

29.

Liao

Lee

et al.

Lamivudine versus entecavir in the rescue of chemotherapy-induced hepatitis B flare-up. J Chin Med Assoc 2017; 80: 758–765.

30.

Pattullo

. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol 2016; 22: 219–237.

31.

Yeo

Johnson

. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209–220.

32.

Loomba

Rowley

Wesley

et al.

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519–528.

33.

Baden

Swaminathan

Angarone

. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14: 882–913.

34.

Liu

et al.

Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: a systematic review and meta-analysis. PLoS One 2017; 12: e0179680–e0179680.

35.

Kwak

Stein

Lim

. Practice patterns in hepatitis B virus screening before cancer chemotherapy in a major US hospital network. Dig Dis Sci 2018; 63: 61–71.